← Leaderboards
Amy Lynn Cavalli
Lpath Therapeutics, Inc.
$1,388,405
Attributed
$1,388,405
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $832.7K · FY2005–07$1M$750K$500K$250K$0
'05
'06
'07
Funding mix
By agency
NIH$1,388,405 · 3
By mechanism
R44$1,107,208 · 1
R43$281,197 · 2
Top collaborators
No co-investigators on record.
Most similar at Lpath Therapeutics, Inc.
Same institution · by research overlap
- Roger Allen Sabbadini$8,234,133
- Rosalia Gerarda Matteo$284,753
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationNeoplasm /Cancer ImmunotherapyMonoclonal AntibodyImmunologic Substance Development /PreparationAntibodiesAthymic MouseAge Related Macular DegenerationBlindnessAngiogenesis InhibitorsBlood VesselsCell MigrationCell PhysiologyCell ProliferationCellsCicatrixBiotechnologyCharacteristicsCollagenComplexDepositionDoseDrug KineticsCell TypeAttenuated
Grant awards (4)
Sphingomab Mitigates the Multiple Pathologies of Age-Related Macular Degeneration$125,844
R43 · FY2007 · EY · contact PI
Anti-sphingolipid antibodies for the treatment of cancer$274,536
R44 · FY2006 · CA · contact PI
Anti-sphingolipid antibodies for the treatment of cancer$832,672
R44 · FY2005 · CA
Anti-sphingolipid antibodies for the treatment of cancer$155,353
R43 · FY2004 · CA